Safety Study of PRLX 93936 in Patients With Advanced Solid Tumors

Inclusion Criteria:

* Histologically confirmed solid tumors
* Tumor progression after receiving standard/approved chemotherapy and for whom no available treatment provides clinical benefit
* One or more metastatic tumors measurable on a CT scan or MRI per RECIST criteria
* ECOG performance 0-1
* Life expectancy of at least 3 months
* Age \>/= 18 years
* A negative pregnancy test (if female of child-bearing potential)
* Acceptable liver function:
* Bilirubin \</= 1.5 times the Upper Limit of Normal (ULN)
* AST (SGOT), ALT (SGPT) and Alkaline phosphatase \</= 2.5 times ULN (if liver metastases are present, then \</= 5 times ULN is allowed)
* Acceptable renal function:
* Serum creatinine within normal limits, OR calculated creatinine clearance \>/= 60 mL/min/1.73m2 for patients with creatinine levels above institutional normal
* Acceptable hematologic status:
* Granulocyte count \>/= 1500 cells/mm3
* Platelet count \>/= 100,000 (plt/mm3)
* Hemoglobin \>/= 9.0 g/dL
* Urinalysis: no clinically significant abnormalities
* Acceptable coagulation status:
* PT within normal limits
* aPTT within normal limits
* Completed any chemotherapy, major surgery, or irradiation at least four weeks before enrollment in this study (six weeks for mitomycin-C or nitrosoureas, and two weeks for "targeted" therapies such as kinase inhibitors). Patient must have recovered from all toxicities incurred as a result of previous therapy.
* QT intervals of QTC \</= 450 msec for men and \</= 470 msec for women (as measured by Hodges equation)
* Left ventricular ejection fraction \>/= 50% by 2D Echocardiogram (or \> institutional lower limits of normal)

Exclusion Criteria:

* NYHA Class III or IV, cardiac disease, myocardial infarction within the past six months, unstable arrhythmia, or evidence of ischemia on ECG
* Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
* Pregnant or nursing women
* Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within four weeks prior to study entry (six weeks for mitomycin-C or nitrosoureas and two weeks for targeted therapies such as kinase inhibitors).
* Unwillingness or inability to comply with protocol procedures
* Known current infection with HIV, hepatitis B or hepatitis C
* Currently receiving any other investigational agent
* Currently receiving medications metabolized by the cytochrome P450 3A4 enzyme pathway
* Presence of clinically apparent central nervous system metastases or carcinomatous meningitis. Patients with brain metastases which are well controlled (patients not taking dexamethasone or anti-seizure medication \>/= three months after treatment) may be enrolled.
* Any other severe concurrent disease, which in the judgement of the investigator would make the patient inappropriate for the study
* Diagnosis of hypertension
* Previously enrolled in this trial